On January 17, Andon Health Co.Ltd(002432) reaped the 28th trading limit, closing at 82.81 yuan / share in late trading, with a cumulative increase of more than 1280% in recent 50 trading days, and the total market value soared from 3 billion yuan to nearly 40 billion yuan. After the closing, the company issued a stock trading risk warning announcement again.
The stock price rose sharply, and the shareholders were very happy. On the interactive trading platform, an investor said that he was very grateful to the company for making a lot of money due to the sharp rise of the company’s share price. He hoped that he and other profitable investors could donate money to the company. The company could use the money to reward employees and make employees work harder.
remind the risk again
Since 2022, Andon Health Co.Ltd(002432) 4 stock trading risk warning announcements have been issued.
In the latest announcement disclosed on January 17, the company said that the single month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent the future performance. The company’s share price is currently at an all-time high, which does not rule out the risk of falling in the future.
Andon Health Co.Ltd(002432) at the same time, in view of the uncertainty of epidemic development and market competition in the United States, it points out that the execution of contracts and orders between U.S. subsidiaries and New York, Massachusetts and the U.S. Department of health and human services is affected by local epidemic situation, the company’s supply chain capacity and other factors, There may be a risk of failure to perform on schedule or in full. The U.S. government can request to stop the execution of the contract and cancel the subsequent procurement without any reason. The Seller shall bear the corresponding risks and possible losses.
also authorized by FDA for emergency use
Since 2022, Andon Health Co.Ltd(002432) has been positive. On the evening of January 12 and before the market on January 14, the company successively put forward two major contract announcements. One said that the U.S. subsidiary has received purchase orders and contracts for ihealth kits from New York and Massachusetts, totaling more than 2.1 billion yuan; Another revealed that the U.S. subsidiary and the U.S. Army contract management command signed a procurement contract on January 13, 2022 local time to sell ihealth kit products. The total contract price tax was US $1.275 billion (including freight), about RMB 8.102 billion.
Andon Health Co.Ltd(002432) on the evening of January 16, it was announced that the professional version Kit (colloidal gold immunochromatography) of covid-19 antigen rapid detection POC (point of care), a U.S. subsidiary, was authorized by the U.S. Food and Drug Administration (FDA) for emergency use (EUA). The product must be tested by professional medical personnel or personnel skilled in using the product in the point of care scene. The company said that the product may bring relevant sales revenue and performance to the company in the future through emergency use authorization.
survey of more than 100 institutions
On the evening of January 16, Andon Health Co.Ltd(002432) announced that more than 100 institutions investigated companies through online meetings on January 14.
Chairman Liu Yi introduced that in 2020, the company’s forehead thermometer products participated in the public health and epidemic prevention work in China and the United States, which opened the market of ihealth brand in the United States. With the development of the epidemic in the United States, ihealth covid-19 home self-test kit has also participated in the epidemic prevention work in the United States. Ihealth received 250 million orders for 500 million kits from the U.S. Department of health and human services, the largest order in its history.
In response to the issue of production capacity, the company responded that China has manufacturing capacity and labor resources. In terms of raw material supply, China’s industrial chain has the ability to supply raw materials by exporting European kits in 2021. The increase of production capacity mainly lies in the supply of labor, but it takes time. At present, the company’s kit products are independent brands and can seek OEM business partners in China. The company will comprehensively consider the two factors of efficiency and risk and reasonably plan the production related arrangements.
Another investor inquired about the market layout of family self-test in other countries, Andon Health Co.Ltd(002432) said that the use of family covid-19 antigen self-test kit is more convenient than nucleic acid test points, and does not rule out the possibility that the product will be used in China or / and other countries in the future. However, the sensitivity of the product is lower than that of nucleic acid detection, and it still needs to be subject to the detection method currently approved by foreign governments in China.
With regard to the future market volume of family self-test kits, the company said that the demand for kits is related to the development of the epidemic, and the attitude of the U.S. government may also change according to the development of the epidemic. Investors can refer to the sales of the company’s forehead thermometer from 2020 to now.
According to the Andon Health Co.Ltd(002432) 2021 semi annual report, the company’s operating revenue in the first half of the year decreased by 45.32% year-on-year to 569 million yuan. The company explained that the operating revenue of its frontal thermometer, oximeter and other epidemic related products increased significantly in the same period of last year, and the gross profit margin of epidemic materials exported overseas was high. The sales prices of epidemic materials and products in this period follow the market, and the gross profit margin is lower than that in the epidemic period.
